πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

8,395 results for β€œLa” Clear

  1. Olaparib 300mg tablets

    AstraZeneca

    Relapsed Ovarian Cancer

    phase 3 small molecule completed

    1 trial

  2. Olaparib, CISPLATIN , Olaparib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED , CARBOPLATIN

    Merck Sharp and Dohme

    Stage IV lung cancer condition

    phase 3 small molecule active

    1 trial

  3. Olaparib, ETOPOSIDE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pembrolizumab placebo (saline), Olaparib matching placebo (tablet), CARBOPLATIN , CISPLATIN , Olaparib

    Merck Sharp and Dohme

    Participants with Limited Stage-Small Cell Lung Cancer, who have received no prior anticancer therapy for their disease.

    phase 3 small molecule active

    1 trial

  4. Olpasiran, Placebo for AMG 890

    Amgen

    Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  5. Olumiant 4 mg film-coated tablets, Placebo of Olumiant 4mg

    Pari Pharma GmbH

    Dermatomyositis; Baricitinib in patients with relapsing or naΓ―ve dermatomyositis.

    phase 3 small molecule active

    1 trial

  6. Omalizumab (Xolair)

    BRIGHT MINDS BIOSCIENCES INC.

    Chronic Urticaria

    phase 3 small molecule completed

    1 trial

  7. Omecamtiv Mecarbil, Omecamtiv Mecarbil, Matching Placebo, Omecamtiv Mecarbil

    Cytokinetics (Ireland) Limited

    Heart Failure With Reduced Ejection Fraction

    phase 3 small molecule active

    1 trial

  8. On-site bundled rapid HIV/HCV testing

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-related Disorders

    phase 3 other completed

    1 trial

  9. Ondansetron Aurobindo 8 mg Filmtabletten, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Dexametazona Krka 4 mg comprimate, EMEND 125 mg+80 mg hard capsules, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer InfusionslΓΆsung, G

    Karyopharm Therapeutics Inc

    Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

    phase 3 small molecule active

    1 trial

  10. Onpattro 2 mg/mL concentrate for solution for infusion., Sodium Chloride Intravenous Infusion BP 0.9% w/v

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

    phase 3 small molecule active

    1 trial

  11. Open Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alpha (PRX-102) 2 mg/kg Administered by Intravenous Infusion Every 4 Weeks in Patients with Fabry Disease

    Chiesi Farmaceutici S.p.A

    Fabry disease (Ξ±-galactosidase A deficiency)

    phase 3 other active

    1 trial

  12. Open Label Topical Beremagene Geperpavec (B-VEC)

    Krystal Biotech Netherlands B.V.

    Dystrophic Epidermolysis Bullosa

    phase 3 mab completed

    1 trial

  13. Open-label pitolisant

    Harmony Biosciences Holdings

    Idiopathic Hypersomnia

    phase 3 small molecule completed

    1 trial

  14. Open-label rusfertide

    Protagonist Therapeutics, Inc

    Polycythemia Vera

    phase 3 small molecule active

    1 trial

  15. Orelabrutinib

    Zenas BioPharma

    Multiple Sclerosis (MS) Primary Progressive

    phase 3 small molecule active

    1 trial

  16. Orelabrutinib

    Zenas BioPharma

    Secondary Progressive Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  17. Orelabrutinib, Placebo tablets match with that of orelabrutinib (ICP-022) tablets in appearance, shape, size, and weight.

    Zenas BioPharma

    Primary Progressive Multiple Sclerosis (PPMS)

    phase 3 small molecule active

    1 trial

  18. Orforglipron, Orforglipron, Orforglipron, Orforglipron, Orforglipron, Orforglipron, Placebo to match LY

    Eli Lilly Co.

    Osteoarthritis

    phase 3 small molecule active

    1 trial

  19. Orforglipron, Orforglipron, Orforglipron, Orforglipron, Placebo to match, Orforglipron, Orforglipron

    Eli Lilly Co.

    Chronic Kidney Disease, Atherosclerosis Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  20. Orforglipron, Orforglipron, Orforglipron, Placebo to match ly, Orforglipron, Orforglipron, Orforglipron

    Eli Lilly Co.

    Peripheral Arterial Disease

    phase 3 small molecule active

    1 trial

  21. Orforglipron, Placebo to match LY, Orforglipron, Orforglipron, Orforglipron, Orforglipron, Orforglipron

    Eli Lilly Co.

    GZP1, GZP2: Obesity, Overweight GZP2: Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  22. Orforglipron, Placebo to match LY3502970

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  23. Otezla 10mg, 20mg, 30 mg film-coated tablets, Matching Placebo for TAK-279 Dose A, ZASOCITINIB, ZASOCITINIB, Matching Placebo for TAK-279 Dose B, Otezla 10mg, 20mg, 30 mg film-coated tablets, Matching Placebo for Apremilast, Otezla 10mg, 20mg, 30 mg film-coated tablets

    Takeda

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  24. Otezla 10mg, 20mg, 30 mg film-coated tablets, Otezla 10mg, 20mg, 30 mg film-coated tablets, Apremilast placebo (same excipient as over-encapsulated Otezla), Otezla 10mg, 20mg, 30 mg film-coated tablets, ZASOCITINIB, Otezla 30 mg film-coated tablets, TAK-279 placebo (same excipient as TAK-279)

    Takeda

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources